The Effect of Health-Related Behaviors on Disease Progression and Mortality in Early Stages of Chronic Kidney Disease: A Nationwide Population-Based Study

Yookyung Lee [1], SuYeon Kwon [1], JongJoo Moon [2], Kyungdo Han [3], Nam-Jong Paik[1] and Won-Seok Kim [1,*]

[1] Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, South Korea; yookon@gmail.com (Y.L); sykwon0502@gmail.com (S.Y.K); njpaik@snu.ac.kr (N.J.P)

[2] Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea; jongjoomoon114@gmail.com

[3] Department of Biostatistics, The Catholic University of Korea College of Medicine, Seoul, South Korea; hkd917@naver.com

* Correspondence: wondol77@gmail.com; Tel.: +82-31-787-7735

Abstract: Healthy life style is associated with decreased risk of chronic kidney disease (CKD) and mortality in the general population. However, there is no definitive evidence on the benefits of physical activity and other health-related behaviors in the early-stage CKD. This study aimed to explore the association between health-related behaviors and end-stage renal disease (ESRD) and mortality in the early stages of CKD. The National Health Insurance Service (NHIS) database from January 1st, 2009 to December 31st, 2016 was used to screen 83,470 subjects with early stage CKD. Cox proportional hazard regression analysis was used to evaluate the association between health-related behaviors and ESRD and death. Kaplan-Meier curves for mortality and ESRD were plotted according to the physical activity, smoking status and alcohol consumption pattern. Risk of death decreased significantly in subjects who engaged in sufficient physical activity (adjusted Hazard Ratio (HR) 0.73; 95% CI: 0.64-0.83; *p* < 0.001). Risk of ESRD and death increased significantly in the current smoker with adjusted HR of 1.44 (95% CI: 1.06-1.95; *p* < 0.02) and 1.61 (95% CI: 1.44-1.80; *p* < 0.001) respectively. Therefore, systematic interventions to encourage physical activity and smoking cessation need to be actively considered in the early stages of CKD.

Keywords: Chronic kidney disease; Disease progression; End stage renal disease; Mortality; Health-related behaviors; Physical activity; Smoking; Alcohol;

1. Introduction

Chronic kidney disease (CKD) is a major global health burden due to its high prevalence and economic cost. The world-wide prevalence of CKD is estimated to be from 11 to 13 % [1]. Increasing prevalence of hypertension, diabetes, and aging societies suggests that the number of CKD patients will further increase in the future [2]. In developed countries, more than 1% of the total health budget is dedicated to the treatment of 0.1% of the population with end-stage renal disease (ESRD) [3].

Previous studies have investigated the relationship between health-related behaviors and CKD in the general population [4–7]. Regular exercise was associated with lower risk of CKD [7]. In a recent meta-analysis, smoking was shown to be an independent risk factor for CKD [6]. Alcohol consumption was associated with decreased risk of CKD [4]. These studies implicate that lifestyle modification may be important in preventing CKD.

According to the 2012 Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines, exercise and smoking cessation are recommended for CKD patients [8]. Exercise may delay the decline of kidney function [9] and lower the risk of cardiovascular disease (CVD), for

47 which CKD is a risk factor [10]. Although the benefits of healthy life style on disease progression
48 and mortality in CKD patients seem straightforward, evidence is sparse, especially in patients with
49 early stages of CKD, who may be the best candidates to benefit from health behavior modifications.
50 Most studies evaluating the relationship between exercise and CKD have been limited by small
51 sample size [9]. Studies including early-stage CKD patients are relatively few and inconclusive [11].
52 There have been mixed results with respect to the effect of alcohol on CKD, with some reporting
53 protective effects while other reporting increased risk [12,13].
54   Therefore, the objective of this study was to investigate the real-world impact of health-related
55 behavioral change on CKD progression and mortality using nationally representative data.
56

2. Materials and Methods

2.1. Data source

59   Most Koreans (97.0%) residing in Korea are covered by one of two health care programs under
60 the National Health Insurance system: the National Health Insurance (NHI) or Medical Aid (MA)
61 [14]. Information on patient demographics, medical service use, disease diagnosis and life style
62 from the two health care programs are incorporated into a single National Health Insurance Service
63 (NHIS) database, accessible for researchers. The Korean NHIS also provides biannual health
64 check-ups which include a questionnaire on past medical history and health-related behaviors,
65 measurements of height, weight, blood pressure, blood count and blood chemistry test [14].
66

2.2. Study cohort for early stages of CKD

68   Using the Korean NHIS database (NHIS-2019-1-101), subjects who received regular health
69 check-up between January 1st, 2009 and December 31st, 2010 were screened (Figure 1). The inclusion
70 criteria were as follows: (1) age 20 to 80 years; (2) without CKD as defined by the estimated
71 glomerular filtration rate (eGFR) $\geq$ 90mL/min/1.73m^2 and negative urine dipstick test at the initial
72 health check-up; (3) record of follow-up health check-up at two years $\pm$ three months from the
73 initial health check-up; and (4) fit the CKD diagnostic criteria, as defined by eGFR > 60
74 mL/min/1.73m^2, and a positive urine dipstick test or eGFR between 30 to 59mL/min/1.73m^2 at the
75 follow-up health check-up (index year) [8]. Subjects with missing data on variables included in the
76 statistical analysis or already diagnosed as ESRD at index year were excluded.

77
78   **Figure 1.** Study design

79

80   *2.3. Health-related behaviors*

81   Health-related behaviors were assessed based on the self-reported questionnaire included in
82   the regular health check-up. Sufficient physical activity was defined as (1) 20 minutes or more of
83   vigorous physical activity, such as running, aerobics, fast bicycling or mountain climbing,
84   performed at least 3 days a week; or (2) 30 minutes or more of moderate physical activity, such as
85   fast walking, doubles tennis or bicycling at a regular pace, performed at least 5 days a week; or (3) 4
86   days of moderate and 1 to 2 days of vigorous physical activity; or (4) 3 days of moderate and 2 days
87   of vigorous physical activity. A current smoker was defined as having smoked more than 100
88   cigarettes in a life time and who was currently smoking daily or intermittently. Alcohol
89   consumption was divided into three levels: heavy drinker, defined as drinking more than 30g
90   alcohol per day; mild drinker, defined as less than 30g alcohol per day; and nondrinker, defined as
91   drinking no alcohol at all.
92

93   *2.4. ESRD and mortality*

94   Subjects were followed-up until December 31st, 2016 for the outcome event of ESRD or
95   mortality. ESRD was defined as the relevant International Classification of Diseases, 10th revision,
96   Clinical Modification (ICD-10-CM) codes (N18-19, Z49, Z94.0, Z99.2) combined with the initiation of
97   renal replacement therapy (R3280, O7011-O7020 or V001, O7071-O7075 or V003). Death from any
98   cause was also obtained from the Korean NHIS database.
99

100   *2.5. Covariate data*

101   Demographic data, such as age, sex, area of residence, and income level were collected. Urban
102   residence was grossly defined as an area with a population of greater than 50,000 according to the
103   Korean Local Autonomy Act. Subjects in the lowest quantile in national health insurance payment
104   or recipients of medical aid were grouped into the low income group.
105   Past medical history, such as diabetes mellitus, hypertension, dyslipidemia, and history of
106   CVD was also gathered. Diabetes mellitus was defined by fasting glucose ≥ 126mg/dL or
107   ICD-10-CM codes of E11-E14 and at least one claim per year for the prescription of antidiabetic
108   medication. Hypertension was defined by blood pressure (BP) ≥ 140/90 or disease codes of I10-I13,
109   and I15, and at least one claim per year for the prescription of antihypertensive medication.
110   Dyslipidemia was defined by total cholesterol ≥ 240mg/dL or a code of E78 and at least one claim
111   per year for the prescription of lipid lowering medication. History of CVD was determined by
112   self-report. If subjects answered yes to one of the following two questions, they were considered to
113   have a history of CVD: (1) Have you been diagnosed or are currently on medication for stroke?; (2)
114   Have you been diagnosed or are currently on medication for heart disease (myocardial
115   infarction/angina)?
116   Charlson Comorbidity Index (CCI) was acquired using ICD-10-CM diagnoses of patients [15].
117   Comorbid conditions were assigned weighted scores based on the relative risk of one year death
118   from the comorbid condition and summed to yield the CCI score. CCI was categorized into three
119   groups: 0, 1 and ≥2.
120   Blood chemistry test results, such as eGFR (calculated using the Modification of Diet in Renal
121   Disease (MDRD) equation), fasting plasma glucose level, serum low-density lipoprotein (LDL), and
122   urine dipstick, body mass index (BMI), and blood pressure, were collected. Fasting glucose, LDL,
123   BMI, and blood pressure were categorized according to the recommended target values in CKD
124   patients (Fasting glucose 90-130mg/dL, LDL 70-100mg/dL, BMI 20-25kg/m², BP<130/80mmHg) [8].
125   Urine dipstick results were categorized as negative, trace, and 1+ or more.
126

127

128   *2.6. Statistical analysis*

129   The baseline characteristics were presented as the mean ± standard deviation or as a number
130   with percentage. Chi-square test was applied for categorical variables, and Student's *t* test was
131   applied for continuous variables to compare the characteristics between the 'Death' and 'No Death'
132   groups, as well as between the 'ESRD' and 'No ESRD' groups. Cox proportional hazard regression
133   analysis was applied to evaluate the association between health-related behaviors (physical activity,
134   smoking, and alcohol) and ESRD and death. The results were adjusted for age, sex, area of
135   residence, income, diabetes mellitus, hypertension, dyslipidemia, history of CVD, health-related
136   behaviors, categorized CCI, urine dipstick, fasting glucose, LDL, BMI, and BP. Kaplan-Meier curves
137   for mortality and ESRD were plotted according to the physical activity, smoking and alcohol. The
138   log rank test was performed to analyze the group differences. All statistical analyses were
139   performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA). A two sided *p* value < 0.05 was
140   considered statistically significant.

141

142   **3. Results**

143   *3.1. Baseline Characteristics*

144   A total of 83,470 subjects with early stages of CKD (mean age 48.43 years; mean baseline eGFR
145   90.48 mL/min/1.73 m²; male 54%) were included in this study (Figure 2). The number of subjects
146   who met the target blood pressure of less than 130/80mmHg, fasting glucose of 90 to 130mg/dL,
147   LDL of 70 to 100mg/dL, and BMI of 20 to 25 kg/m² was 38,825 (46.51%), 46,947 (56.24%), 22,478
148   (26.93%), and 43,758 (52.42%) respectively (Table 1).

149

150   **Figure 2.** Patient flow. CKD, Chronic Kidney Disease; ESRD, End Stage Renal Disease.

151

152

Table 1. Baseline characteristics of study population

		Death			ESRD		
	Total	**No**	**Yes**	***p* Value**	**No**	**Yes**	***p* Value**
N	**83,470**	**81,664**	**1,806**		**83,237**	**233**	
Age, years, mean ± SD	48.43±13.34	48.09±13.16	64.05±12.02	<.001	48.41±13.33	57.24±12.97	<.001
Male, n, (%)	45,108(54.04)	43,835(53.68)	1,273(70.49)	<.001	44,935(53.98)	173(74.25)	<.001
Urban residence, n, (%)	37,732(45.2)	37,064(45.39)	668(36.99)	<.001	37,652(45.23)	80(34.33)	<.001
Low Income, n, (%)	12,956(15.52)	12,562(15.38)	394(21.82)	<.001	12,893(15.49)	63(27.04)	<.001
Diabetes Mellitus, n, (%)	13,047(15.63)	12,383(15.16)	664(36.77)	<.001	12,931(15.54)	116(49.79)	<.001
Hypertension, n, (%)	27,346(32.76)	26,275(32.17)	1,071(59.3)	<.001	27,188(32.66)	158(67.81)	<.001
Dyslipidemia, n, (%)	21,377(25.61)	20,801(25.47)	576(31.89)	<.001	21,275(25.56)	102(43.78)	<.001
History of CVD, n, (%)	1,326(1.59)	1,198(1.47)	128(7.09)	<.001	1,312(1.58)	14(6.01)	<.001
CCI, n, (%)				<.001			<.001
0	42,039(50.36)	41,654(51.01)	385(21.32)		41,994(50.45)	45(19.31)	
1	20,782(24.9)	20,452(25.04)	330(18.27)		20,751(24.93)	31(13.3)	
2 or more	20,649(24.74)	19,558(23.95)	1,091(60.41)		20,492(24.62)	157(67.38)	
Sufficient physical activity, n, (%)	16,854(20.19)	16,550(20.27)	304(16.83)	<.001	16,810(20.2)	44(18.88)	0.619
Smoking, n, (%)				<.001			<.001
No	49,476(59.27)	48,590(59.5)	886(49.06)		49,367(59.31)	109(46.78)	
Ex	13,451(16.11)	13,086(16.02)	365(20.21)		13,405(16.1)	46(19.74)	
Current	20,543(24.61)	19,988(24.48)	555(30.73)		20,465(24.59)	78(33.48)	
Alcohol consumption, n, (%)				<.001			0.007
No	41,602(49.84)	40,533(49.63)	1,069(59.19)		41,466(49.82)	136(58.37)	
Mild	34,622(41.48)	34,102(41.76)	520(28.79)		34,549(41.51)	73(31.33)	
Heavy	7,246(8.68)	7,029(8.61)	217(12.02)		7,222(8.68)	24(10.3)	
eGFR, ml/min/1.73m², n, (%)				<.001			<.001
30-59	16,365(19.61)	15,760(19.3)	605(33.5)		16,269(19.55)	96(41.2)	
60-89	25,042(30)	24,508(30.01)	534(29.57)		24,963(29.99)	79(33.91)	
90-	42,063(50.39)	41,396(50.69)	667(36.93)		42,005(50.46)	58(24.89)	
Urine Dipstick, n, (%)				<.001			<.001
Negative	15,344(18.38)	14,820(18.15)	524(29.01)		15,284(18.36)	60(25.75)	
Trace	39,384(47.18)	38,822(47.54)	562(31.12)		39,341(47.26)	43(18.45)	
1+ or more	28,742(34.43)	28,022(34.31)	720(39.87)		28,612(34.37)	130(55.79)	
Fasting Glucose, n, (%)				<.001			<.001
<90	27,850(33.37)	27,508(33.68)	342(18.94)		27,798(33.4)	52(22.32)	
90-130	46,947(56.24)	45,909(56.22)	1,038(57.48)		46,837(56.27)	110(47.21)	
>130	8,673(10.39)	8,247(10.1)	426(23.59)		8,602(10.33)	71(30.47)	
LDL, mg/dL, n, (%)				<.001			0.059

<70	7,924(9.49)	7,596(9.3)	328(18.16)		7,894(9.48)	30(12.88)
70-100	22,478(26.93)	21,992(26.93)	486(26.91)		22,407(26.92)	71(30.47)
>100	53068(63.58)	52076(63.77)	992(54.93)		52,936(63.6)	132(56.65)
BMI, n, (%)				<.001			0.631
<20	10,247(12.28)	9,960(12.2)	287(15.89)		10,223(12.28)	24(10.3)
20-25	43,758(52.42)	42,774(52.38)	984(54.49)		43,635(52.42)	123(52.79)
>25	29,465(35.3)	28,930(35.43)	535(29.62)		27,379(35.3)	86(36.91)
BP > 130/80mmHg, n, (%)	44,645(53.49)	43,452(53.21)	1,193(66.06)	<.001	44,481(53.44)	164(70.39)	<.001

Statistical analysis: chi-square test and Student's *t* test. Abbreviations: SD, standard deviation; CVD, cardiovascular disease; CCI, Charlson comorbidity index; eGFR, estimated glomerular filtration rate; LDL, low density lipoprotein; BMI, body mass index; BP, blood pressure;

3.2. Health-related behaviors and risk of ESRD and death

3.2.1. Physical Activity

Approximately 20% of subjects reported to be engaged in sufficient physical activity. There was a significantly higher survival rate in the sufficient physical activity group, but no significant difference in the ESRD progression rate in the unadjusted Kaplan-Meier analysis (Figure 3a, b). The risk of death was significantly decreased in subjects who engaged in sufficient physical activity (adjusted Hazard Ratio (HR) 0.73; 95% CI: 0.64-0.83; $p < 0.001$) (Table 2). In addition, a tendency towards decreased risk of ESRD was observed, but without statistical significance (adjusted HR 0.84; 95% CI: 0.60-1.17; $p = 0.30$).

3.2.2. Smoking

Approximately 25% of the total subjects were current smokers. According to the unadjusted Kaplan-Meier analysis, current smokers showed a significantly lower survival rate and higher ESRD progression rate (Figure 3c, d). Risk of ESRD and death increased significantly in the current smoking group with respective adjusted HR of 1.44 (95% CI: 1.06-1.95; $p < 0.02$), and 1.61 (95% CI: 1.44-1.80; $p < 0.001$) (Table 2).

3.2.3. Alcohol consumption

Approximately 50% of total subjects were alcohol drinkers. Alcohol drinkers showed a significantly higher survival rate and lower ESRD progression rate in the unadjusted Kaplan-Meier analysis (Figure 3e, f). The risk of ESRD and death decreased significantly in the alcohol drinking group with adjusted HR of 0.59 (95% CI: 0.44-0.79; $p < 0.001$) and 0.83 (95% CI: 0.74-0.93; $p < 0.001$), respectively (Table 2).

184
185   **Table 2.** Health-related behaviors and risk of ESRD and death

	N	ESRD	Follow-up duration (person* year)	Crude HR (95%CI)	Adjusted HR (95%CI)[a]	Death	Follow-up duration (person* year)	Crude HR (95%CI)	Adjusted HR (95%CI)[a]
Smoking									
Non, Ex	62,927	155	336,424.23	1(ref.)	1(ref.)	1,251	336,675.06	1(ref.)	1(ref.)
Current	20,543	78	108,623.67	1.41 (1.04,1.90)	1.44 (1.06,1.95)	555	108,733.86	1.7 (1.52,1.90)	1.61 (1.44,1.80)
p-value				0.03	0.02			<.001	<.001
Alcohol									
Non	41,602	136	222,490.34	1(ref.)	1(ref.)	1,069	222,719.88	1(ref.)	1(ref.)
<30g/day or >30g/day	41,868	97	222,557.55	0.60 (0.45,0.80)	0.59 (0.44,0.79)	737	222,689.04	0.87 (0.79,0.97)	0.83 (0.74,0.93)
p-value				<.001	<.001			0.01	<.001
Physical activity									
Insufficient	66,616	189	354,888.68	1(ref.)	1(ref.)	1,502	355,182.57	1(ref.)	1(ref.)
Sufficient	16,854	44	90,159.22	0.79 (0.57,1.1)	0.84 (0.60,1.17)	304	90,226.35	0.69 (0.61,0.78)	0.73 (0.64,0.83)
p-value				0.16	0.30			<.001	<.001

186   [a] Adjusted for age, sex, area of residence, income, diabetes mellitus, hypertension, dyslipidemia, history of CVD,
187   CCI, exercise, smoking, alcohol, urine dipstick, fasting glucose, LDL, BMI, BP
188   Statistical analysis: Cox proportional hazard regression analysis. Abbreviations: ESRD, end stage renal disease;
189   HR, hazard ratio; 95% CI, 95% confidence interval; CVD, cardiovascular disease; CCI, Charlson comorbidity
190   index; LDL, low density lipoprotein; BMI, body mass index; BP, blood pressure;

Figure 3. Kaplan-Meier curves for end-stage renal disease (ESRD) and mortality according to sufficient physical activity (PA) (**A, B**), smoking (**C, D**), and alcohol consumption (**E, F**).

4. Discussion

Health-related behaviors are associated with disease progression and mortality in CKD patients. Subjects who engage in sufficient physical activity had a significantly lower risk of death than those with insufficient physical activity. Current smokers had a significantly higher risk of ESRD and death than their non-smoking counterparts. Alcohol drinkers had a significantly lower risk of ESRD and death than non-drinkers (Table 2).

A prospective cohort study, based on the Cardiovascular Health Study, reported that physical activity decreased the risk of CKD progression, as defined by a loss of 3.0 ml/min/1.73 m² per year in GFR [16]. In our study, the risk of CKD progression, as defined by ESRD, was not significantly

lower in subjects who engage in sufficient physical activity. This may have been because ESRD as an endpoint was less sensitive than the decrease in GFR by certain percent or amount. In addition, the follow-up time of up to 6 years may have been short in detecting the occurrence of ESRD in our study of subjects with early-stage CKD. A previous study showed that patients had minimal progression of CKD over a period of 6 years [17].

Previous studies reported that physical activity decreased all-cause mortality in the general population and in ESRD patients on renal replacement therapy [18–20]. Our study reproduced the results of previous studies in the early-stage CKD population. Although the exact mechanism remains uncertain, exercise is thought to decrease the risk of death by improving metabolic factors and decreasing risk of CVD [21]. In addition, physical activity can reduce muscle wasting, which is a cause of premature death in ESRD patients [22,23]. Despite benefits of physical activity in CKD patients, only 20% of patients engaged in sufficient physical activity (Table 1). Therefore, more aggressive life style interventions and systematic efforts are needed in patients in the early-stage CKD to delay disease progression and possible death.

Smoking significantly increased the risk of ESRD and death in early-stage CKD patients. Our study reproduced the results of previous studies. A recent meta-analysis study showed that current smokers had an OR of 1.91 (95% CI: 1.39-2.64) for ESRD [6]. Mortality HR for all causes in male and female current smokers with CKD were 2.26 (95% CI: 1.95-2.63) and 1.78 (95% CI: 1.36-2.32), respectively [24]. Despite the detrimental effects of smoking on CKD progression and death in CKD patients, 25% of patients with early-stage CKD were still currently smoking (Table 1). Therefore, active interventions to quit smoking are also needed to be incorporated in routine health-checkups with a focus on patients with early-stage CKD.

Alcohol consumption was associated with lower risk of ESRD and death in patients with early-stage CKD. The results of previous studies on the effect of alcohol consumption and risk of ESRD and death in CKD patients have been mixed. Contrary to our results, a previous meta-analysis reported a relative risk (RR) of 1.00 (95% CI: 0.55-1.82) for ESRD in CKD patients with high alcohol consumption [5]. This may have been due to the differences in the method of comparison of alcohol consumption. Our study compared no alcohol consumption with alcohol consumption, while the meta-analysis compared alcohol consumption with high alcohol consumption. A previous study reported a mortality risk for alcohol consumption of more than 2 drinks a week in CKD patients as 0.67 (95% CI: 0.48-0.94) [10]. Alcohol is thought to prevent hyalinization of renal arterioles, increase high-density lipoprotein (HDL) cholesterol, and reduce inflammation by controlling the plasma fibrinogen and IL-1 alpha levels [4]. Polyphenol in red wine has an antioxidant effect. These mechanisms are thought to be involved in the protection of kidney function with alcohol consumption [4]. However, caution is needed in interpreting these results into clinical practice, since the optimal alcohol consumption level is not yet clear and may be hard to control.

The strengths of our study are as follows: large sample size of patients in the early stages of CKD, nationally representative data, and longitudinal follow-up of up to 6 years. Detailed information from the health-checkup data was used, and possible confounders such as socioeconomic variables, comorbidities and blood chemistry test results, were included into a comprehensive analysis.

Nonetheless, there are several limitations to consider as well. First, urine dipstick was used in the definition of CKD instead of proteinuria, which is more sensitive. Second, the data on health-related behaviors were based on self-report, which may be highly subjective and not very reliable. Studies have shown that subjects tend to overestimate their physical activity level in self-reports [25]. However, if physical activity levels were overestimated, it only implies that more subjects do not engage in sufficient physical activity and that mortality risk can be decreased with even less physical activity. Similarly subjects tend to underreport alcohol consumption [5]. Since our study compared the no-alcohol consumption group to the alcohol consumption group, slight underestimation of alcohol consumption will likely not impact our study results. Third, subjects who did not receive health check-up were excluded, increasing the risk of selection bias. Fourth, not

254 all possible confounding factors, such as medication or sarcopenia, were considered [26]. Lastly, the
255 different etiologies of CKD were not taken into consideration.

5. Conclusions

257 In early CKD patients, sufficient physical activity is associated with decreased risk of mortality.
258 Smoking is associated with increased risk of ESRD and death. However, only 20% of CKD patients
259 engaged in sufficient physical activity and 25% of patients continued to smoke. Therefore,
260 interventions to modify health-related behaviors during the early stages of CKD should be
261 considered and promoted.

262 **Author Contributions:** Conceptualization, N.J.P., W-S.K. and S.Y.K.; methodology and design, W-S.K, S.Y.K,
263 K.H., Y.L. and J.J.M.; formal analysis and interpretation, K.H., Y.L., and W-S.K.; writing—original draft
264 preparation, Y.L.; writing—review and editing, N.J.P., K.H., S.Y.K., J.J.M., Y.L., and W-S.K.; supervision, N.J.P.
265 and W-S.K. All named authors have read the manuscript, have agreed to the submission, and have participated
266 in the study to a sufficient extent to be named as authors. All listed authors agreed with the content and
267 presentation of the paper.

272 **Conflicts of Interest:** The authors declare no conflict of interest.

References

274 1.   Hill, N.R.; Fatoba, S.T.; Oke, J.L.; Hirst, J.A.; Callaghan, A.O.; Lasserson, D.S.; Hobbs, F.D.R. Global
275   Prevalence of Chronic Kidney Disease – A Systematic Review and Meta-Analysis. *Plosone* **2016**, 1–18.
276 2.   Jha, V.; Garcia-Garcia, G.; Iseki, K.; Li, Z.; Naicker, S.; Plattner, B.; Saran, R.; Wang, A.Y.M.; Yang, C.W.
277   Chronic kidney disease: Global dimension and perspectives. *Lancet* **2013**, *382*, 260–272.
278 3.   Nugent, R.A.; Fathima, S.F.; Feigl, A.B.; Chyung, D. The burden of chronic kidney disease on
279   developing nations: a 21st century challenge in global health. *Nephron. Clin. Pract.* **2011**, *118*, c269-77.
280 4.   Kanda, E.; Muneyuki, T.; Suwa, K.; Nakajima, K. Alcohol and exercise affect declining kidney function
281   in healthy males regardless of obesity: A prospective cohort study. *PLoS One* **2015**, *10*, 1–11.
282 5.   Cheungpasitporn, W.; Thongprayoon, C.; Kittanamongkolchai, W.; Brabec, B.A.; O'corragain, O.A.;
283   Edmonds, P.J.; Erickson, S.B. High alcohol consumption and the risk of renal damage: A systematic
284   review and meta-analysis. *Qjm* **2015**, *108*, 539–548.
285 6.   He, L.; Ma, Z.; Su, X.; Gao, Y.; Xia, J.; Wang, L.; Wang, Y.; Zhong, L. Cigarette smoking and chronic
286   kidney disease in the general population: a systematic review and meta-analysis of prospective cohort
287   studies. *Nephrol. Dial. Transplant.* **2017**, *32*, 475–487.
288 7.   Wakasugi, M.; Kazama, J.J.; Yamamoto, S.; Kawamura, K.; Narita, I. A combination of healthy lifestyle
289   factors is associated with a decreased incidence of chronic kidney disease: A population-based cohort
290   study. *Hypertens. Res.* **2013**, *36*, 328–333.
291 8.   Willis, K.; Cheung, M.; Slifer, S. KDIGO 2012 Clinical Practice Guideline for Evaluation & Management
292   of CKD. *Kidney Int. Suppl.* **2013**, *3*.
293 9.   Izumi, A.; Kitamura, M.; Izawa, K.P. Effects of Exercise Training on Delaying Disease Progression in
294   Patients with Chronic Kidney Disease: a Review of the Literature. *Rev. Recent Clin. Trials* **2016**, *11*,
295   333–341.

296   10.   Shlipak, M.G.; Newman, A.; Peterson, D.; Siscovick, D.; Stehman-Breen, C.; Cushman, M.; Psaty, B.;
297   Bleyer, A.; Fried, L.F.; Manolio, T.A. Cardiovascular Mortality Risk in Chronic Kidney Disease. *Jama*
298   **2005**, *293*, 1737.

299   11.   Barcellos, F.C.; Santos, I.S.; Umpierre, D.; Bohlke, M.; Hallal, P.C. Effects of exercise in the whole
300   spectrum of chronic kidney disease: A systematic review. *Clin. Kidney J.* **2015**, *8*, 753–765.

301   12.   Shankar, A.; Klein, R.; Klein, B.E.K. The association among smoking, heavy drinking, and chronic
302   kidney disease. *Am. J. Epidemiol.* **2006**, *164*, 263–271.

303   13.   Ryoo, J.H.; Choi, J.M.; Oh, C.M.; Kim, M.G. The association between uric acid and chronic kidney
304   disease in Korean men: A 4-year follow-up study. *J. Korean Med. Sci.* **2013**, *28*, 855–860.

305   14.   Song, S.O.; Jung, C.H.; Song, Y.D.; Park, C.Y.; Kwon, H.S.; Cha, B.S.; Park, J.Y.; Lee, K.U.; Ko, K.S.; Lee,
306   B.W. Background and data configuration process of a nationwide population-based study using the
307   Korean national health insurance system. *Diabetes Metab. J.* **2014**, *38*, 395–403.

308   15.   Hude Quan, Vijaya Sundararajan, Patricia Halfon, Andrew Fong, Bernard Burnand, Jean-Christophe
309   Luthi, L. Duncan Saunders, Cynthia A. Beck, Thomas E. Feasby, W.A.G. Coding Algorithms for
310   Defining Comorbidities in. *Med Care* **2005**, *43*, 1130–1139.

311   16.   Cassianne Robinson-Cohen, Ronit Katz, Dariush Mozaffarian, Lorien S Dalrymple, Ian de Boer, Mark
312   Sarnak, Mike Shlipak, David Siscovick, B.K. Physical Activity and Rapid Decline in Kidney Function.
313   *Arch Intern Med* **2010**, *169*, 2116–2123.

314   17.   Altemtam, N.; Russell, J.; El Nahas, M. A study of the natural history of diabetic kidney disease (DKD).
315   *Nephrol. Dial. Transplant* **2012**, *27*, 1847–1854.

316   18.   Stack, A.G.; Molony, D.A.; Rives, T.; Tyson, J.; Murthy, B.V.R. Association of physical activity with
317   mortality in the US dialysis population. *Am. J. Kidney Dis.* **2005**, *45*, 690–701.

318   19.   Wen, C.P.; Wai, J.P.M.; Tsai, M.K.; Yang, Y.C.; Cheng, T.Y.D.; Lee, M.C.; Chan, H.T.; Tsao, C.K.; Tsai,
319   S.P.; Wu, X. Minimum amount of physical activity for reduced mortality and extended life expectancy:
320   A prospective cohort study. *Lancet* **2011**, *378*, 1244–1253.

321   20.   Beddhu, S.; Baird, B.C.; Zitterkoph, J.; Neilson, J.; Greene, T. Physical Activity and Mortality in Chronic
322   Kidney Disease (NHANES III). *Clin. J. Am. Soc. Nephrol.* **2009**, *4*, 1901–1906.

323   21.   Stump, C.S. Physical Activity in the Prevention of Chronic Kidney Disease. *Cardiorenal Med.* **2011**, *1*,
324   164–173.

325   22.   Stenvinkel, P.; Carrero, J.J.; Von Walden, F.; Ikizler, T.A.; Nader, G.A. Muscle wasting in end-stage renal
326   disease promulgates premature death: Established, emerging and potential novel treatment strategies.
327   *Nephrol. Dial. Transplant.* **2016**, *31*, 1070–1077.

328   23.   Xiaonan H. Wang, Mitch, W.E. Mechanisms of muscle wasting in chronic kidney disease. *Nat Rev*
329   *Nephrol.* **2014**, *10*, 504–516.

330   24.   Nakamura, K.; Nakagawa, H.; Murakami, Y.; Kitamura, A.; Kiyama, M.; Sakata, K.; Tsuji, I.; Miura, K.;
331   Ueshima, H.; Okamura, T. Smoking increases the risk of all-cause and cardiovascular mortality in
332   patients with chronic kidney disease. *Kidney Int.* **2015**, *88*, 1144–1152.

333   25.   Lee, P.H.; Macfarlane, D.J.; Lam, T.H.; Stewart, S.M. Validity of the international physical activity
334   questionnaire short form (IPAQ-SF): A systematic review. *Int. J. Behav. Nutr. Phys. Act.* **2011**, *8*, 115.

335   26.   Souza, V.A. de; Oliveira, D. de; Mansur, H.N.; Fernandes, N.M. da S.; Bastos, M.G. Sarcopenia in
336   Chronic Kidney Disease. *J. Bras. Nefrol.* **2015**, *37*.

337

338